Strategic Partnering Opportunities

Concert Pharmaceuticals is applying its platform technology in deuterium chemistry to develop novel and differentiated small molecule patentable drugs. Concert has a broad pipeline of proprietary drug candidates in the areas of HIV, pain/spasticity, GI motility, infectious disease (MRSA, HCV, other) epilepsy, oncology, diabetic nephropathy, among others. Concert’s business strategy is to utilize collaborative pharmaceutical partnerships to drive these new chemical entities through development and commercialization to address unmet medical needs.

For further information please contact: Greg Miller Head of Business and Corporate Development 781.674.5227 BD@concertpharma.com

E-Newsletter Subscribe to Concert's quarterly business development newsletter to receive R&D updates, corporate news and more via e-mail. Sign up for our BD Newsletter

Current Partners
GlaxoSmithKline - 2009

Corporate Materials

• Fact Sheet: Deuterated Chemical Entity (DCE) Platform
• Publication: Innovations in Pharmaceutical Technology, "The Development of Deuterium Containing Drugs."
• Publication: Drug Discovery & Development: Chemistry for Drug Development: Deuterium Modification
• Concert's scientific poster presentations are available upon request.
  

Upcoming Events

American Conference Institute's 16th Advanced Forum on:
Life Sciences Collaborative Agreements and M&A
New York, NY
February 27-28, 2012

BioNetwork East 2012
Miami, FL
March 5-7, 2012

2012 Business Development Biotech Conference
Boston, MA
April 16-17 2012

Allicense 2012
San Francisco, CA
May 1-2, 2012

[ back to top ]